View
Page
Read Panmure Gordon & Co's note on Aveva, out this morning on Research Tree: "Final results are in line with guidance. For us the positive is Asia - not as bad as feared, and balancing this, exceptional costs are higher than we had anticipated. Ahead of meeting the company we have elected to leave estimates unchanged. The valuation remains a bit toppy for now, with EV/EBITDA at 14.3 and no news of the ‘special’ which we had been arguing for. We are relaxed with our Hold..."
Latest from the Community...
Latest from the Community...
Latest from the Community...